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Abstract
Rationale Cannabis and tobacco are often smoked simulta-
neously in joints, and this practice may increase the risks of
developing tobacco and/or cannabis use disorders. Currently,
there is no human experimental research on how these drugs
interact on addiction-related measures.
Objectives This study aimed to investigate how cannabis and
tobacco, each alone and combined together in joints, affected
individuals’ demand for cannabis puffs and cigarettes, explicit
liking of drug and non-drug-related stimuli and craving.
Method A double-blind, 2 (active cannabis, placebo cannabis) ×
2 (active tobacco, placebo tobacco) crossover design was used
with 24 non-dependent cannabis and tobacco smokers. They
completed a pleasantness rating task (PRT), amarijuana purchase
task (MPT) and a cigarette purchase task (CPT) alongside mea-
sures of craving pre- and post-drug administration.
Results Relative to placebo cannabis, active cannabis reduced
liking of cannabis-associated stimuli and increased response
time to all stimuli except cigarette-related stimuli. Relative to
placebo cannabis, active cannabis decreased demand for can-
nabis puffs (trends for breakpoint and elasticity) and cigarettes
(breakpoint, Pmax, Omax) on several characteristics of the pur-
chase tasks. We found no evidence that active tobacco, both
alone or combined with cannabis, had an effect on liking,
demand or craving.
Conclusions Acutely, cannabis reduced liking of cannabis-
related stimuli and demand for cannabis itself. Acute canna-
bis also reduced demand for cigarettes on the CPT. Acute
tobacco administration did not affect demand or pleasantness
ratings for cigarettes themselves or cannabis. In non-
dependent cannabis and tobacco co-users, tobacco did not
influence the rewarding effects of cannabis.
Keywords Cannabis . Tobacco . Co-administration .
Behavioural economics . Craving . Reward . Liking
Introduction
Cannabis and tobacco are often smoked at the same time in the
same preparation (e.g. in a ‘joint’ or ‘spliff’), and this is referred
to as co-administration. Prevalence of simultaneous use of can-
nabis with tobacco amongst cannabis users is very high in the
UK (77.2%) and across Europe (81.4–90.9%) as well as
Australasia (20.7–51.6%) with the most prevalent route of ad-
ministration being joints with tobacco (Hindocha et al. 2016).
Although both drugs have reinforcing effects (Justinova et al.
2008; Shoaib et al. 1997), the cumulative probability of devel-
oping dependence across one’s lifetime is 67.5% for tobacco
users and 8.9% for cannabis users, suggesting that tobacco is
more addictive than cannabis (Lopez-Quintero et al. 2011). In a
recent study of young adults in theUK, it was found that cigarette
smoking increased the addictive potential of cannabis as it me-
diated the relationship between the frequency of cannabis use
and dependence on the drug itself (Hindocha et al. 2015b).
However, none of these studies adequately encapsulates the im-
pact of co-administration with tobacco, which can acutely influ-
ence the subjective and cognitive effects of cannabis (Hindocha
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et al. 2017a; Schuster et al. 2016). The observational data is
further limited as it is extremely challenging to disassociate the
effects of cannabis from tobacco and to further isolate the acute
effects of the drugs from residual and chronic drug effects.
Delta-9-tetrahydrocannabinol (THC), the primary psycho-
active component of cannabis, and nicotine are partial ago-
nists at the cannabinoid receptor 1 (e.g. CB1R) and acetylcho-
line receptors (nAChr), respectively. Preclinical data suggests
a functional and bidirectional relationship between the canna-
binoid and cholinergic systems that may bemediated by struc-
tures involved inmotivation (Cohen et al. 2002). For example,
prior exposure to THC increases the addictive effects of nico-
tine (Panlilio et al. 2013). The CB1R is critical to the reward-
ing effects of nicotine, such that in CB1R knock-out mice, the
rewarding effects of nicotine are null (Castañé et al. 2002). To
our knowledge, there has been no research on how co-
administered cannabis and tobacco may influence aspects of
reward processing related to these drugs in humans.
Berridge and Robinson (2003) separated reward processing
into distinct components including ‘wanting’ and ‘liking’, each
with separate implicit and explicit sub-components. The de-
mand for drugs, relative to money, can be measured by pur-
chase tasks (MacKillop et al. 2008) which give a real-world
indication of the value of drugs (Bickel et al. 2014) and most
likely capture aspects of explicit motivation. Purchase tasks are
behavioural economic measures that quantify the association
between drug consumption and price (MacKillop and
Murphy 2013; Murphy and MacKillop 2006). Performance
on the cigarette purchase task (CPT) has been associated with
nicotine dependence, daily smoking and objective measures
such as carbon monoxide levels (Mackillop et al. 2016;
MacKillop et al. 2008). The marijuana purchase task (MPT)
has shown associations with age of onset, craving and frequen-
cy of cannabis use (Aston et al. 2015; Collins et al. 2014). Most
recently, a state version of the MPT has shown sensitivity to
experimentally induced craving (Metrik et al. 2016) whereby
cannabis demand indices increased and participants became
less sensitive to price after a cue-reactivity paradigm (Metrik
et al. 2016). However, no study has yet to investigate how acute
cannabis, both individually and in combination with tobacco,
affects demand for cigarettes and cannabis.
Explicit liking of drug-associated stimuli also plays a role in
the reinforcing value of a drug. It can be indexed by pleasant-
ness rating task (PRT), and the response may be related to
hedonic processes involved in drug abuse (Morgan et al.
2010). Users of cannabis with high levels of THC in it have
been shown to have greater explicit liking of cannabis images
(Morgan et al. 2010); however, acute cannabis intoxication
also produces a satiety response and therefore reducing liking
overall (Metrik et al. 2015). On the other hand, findings on the
relationship between cigarette use and drug and non-drug re-
ward processing have been mixed (Lawn et al. 2015; Mogg
et al. 2003; Powell et al. 2002). It is possible that cannabis and
tobacco together may affect the hedonic responses to both
drug and non-drug rewards; however, this possibility has not
been investigated. Indeed, both have been implicated in food
responses where they have opposite effects, cannabis stimu-
lates appetite, whilst nicotine appears to decrease appetite
(Kirkham 2005; Picciotto 2003). We differentiate effects of
cannabis, tobacco and their combination on the subjective
liking associated with cannabis, cigarette and food stimuli.
The present study aimed to investigate how acute administra-
tion of cannabis and tobacco, both alone and combined, would
influence demand (for cannabis puffs and cigarettes), explicit
liking of pictorial stimuli (cannabis, cigarette, food and neutral)
and craving for cannabis, cigarettes and food. In light of the
legalisation and medicalisation of cannabis, in this study, we
recruited recreational cannabis and tobacco using a group who
was not dependent on either drug but may be vulnerable to the
development of addiction. This population would not experience
withdrawal symptoms and would not have interference from
residual or chronic drug effects. This study is clinically relevant
as it investigates acute effects of cannabis and tobacco, both
individually and in a potentially at-risk group, thus allowing us
to understand the mechanism by which these users may transi-
tion to harmful use/dependence.
We firstly hypothesised that administration of either drug
alone would reduce demand, liking and craving for that sub-
stance because of satiety (e.g. administrating active cannabis
would reduce demand/liking/craving for cannabis). Secondly,
we hypothesised that administration of one drug would increase
demand, craving and liking for the other substance because of
the strong association between cannabis and tobacco in individ-
uals who use both together (e.g. administering cannabis without
active tobacco would increase demand/liking/craving for tobac-
co). Finally, we hypothesised that cannabis would increase
craving/liking of food-related stimuli and predicted the opposite
pattern for tobacco.
Method
Design and participants
A randomised, double-blind, placebo-controlled four-way cross-
over trial was used to investigate the acute effects of cannabis and
tobacco, both alone and combined. Participants attended four
sessions, separated by at least 1 week (>3 times the half-life of
THC (Hindocha et al. 2015a)) in a randomised order determined
by a Latin square. Previous data from this study has been pub-
lished elsewhere focussing on memory and psychotomimetic
effects (Hindocha et al. 2017a) and validation of self-reported
dose per joint (Hindocha et al. 2017b). The estimated sample
size of 24 was based on a previous four-way crossover study
examining the interactive effects of THC and CBD (Hindocha
et al. 2015a). This would achieve an effect size of d = 0.5 with
Psychopharmacology
80% power at an alpha of 0.05 (G*power version 3.1.9.2) (Faul
et al. 2007). Participants from the community were recruited
through posters around London universities and on online notice
boards. All participants provided written, informed consent.
Ethical approval was given by the UCL Ethics Committee.
Inclusion criteria were (i) age 18–60 years; (ii) regular use
(>once per month and <3 times a week) of cannabis mixed with
tobacco in joints for the previous 6 months (Lawn et al. 2016);
(iii) normal or corrected to normal vision; (iv) fluent English;
(v) self-reported abstinence from tobacco, cannabis, alcohol
and other drugs for at least 12 h prior to each test day; (vi)
alveolar carbon monoxide (CO) ≤6 ppm to confirm no recent
smoking on each test day (Cooper and Haney 2009); and (vii)
self-reported ability to smoke one whole ‘standard’ joint which
is considered a relatively high bar as common practise is to
share joints in recreational users (Lawn et al. 2016).
Exclusion criteria were (i) scoring ≥3 on the Cannabis
Severity of Dependence Scale (SDS; Gossop et al. 1995);
(ii) seeking treatment for cannabis or tobacco use or currently
using nicotine replacement therapy or other cessation pharma-
cotherapy; (iii) smoking ≥10 cigarettes a day or scoring ≥4 on
the Fagerstrom Test of Nicotine Dependence (FTND
(Heatherton et al. 1991)); (iv) first cigarette smoked within
the first 3 h after waking (to ensure results were not simply
due to reversal of withdrawal from tobacco (Jarvik et al.
2000)); (v) significant respiratory or physical disorder or a
clinically diagnosed learning impairments; (vi) clinically di-
agnosed schizophrenia or psychosis (or a first-degree family
member with either) or substance use disorder and (vii) use of
illicit substance use other than cannabis more than once per
week.
Drug administration (Fig. 1/Table 1)
We compared the effects of (a) active cannabis + active tobacco
(CAN-TOB), (b) active cannabis + placebo tobacco (CAN), (c)
placebo cannabis + active tobacco (TOB) and (d) placebo can-
nabis + placebo tobacco (no active drug) (PLACEBO). The dose
of cannabis and tobacco specified in Table 1 was based on pre-
vious experimental studies reporting robust subjective, cardio-
vascular, psychotomimetic and memory-impairing effects
(Lawn et al. 2016; Mokrysz et al. 2016) for cannabis and a
reliable increase in peak plasma nicotine levels of >20 ng/ml
for tobacco (Mendelson et al. 2005; Mendelson et al. 2003).
This is also similar to a standard cannabis + tobacco joint
(Hunault et al. 2009; van der Pol et al. 2014). Placebo cannabis
is produced from active cannabis and contains less than 0.1%
THC (butwith the same terpene content, so it retains the look and
smells of cannabis). Placebo tobacco was the same dose of very
low nicotine (VLN; typically referred to as denicotinised) tobac-
co (Magic 0 (XXII CenturyGroupLtd)). The smoking procedure
was standardised to control for dose titration and maximise ab-
sorption of THC (Ramaekers et al. 2006). The smoking proce-
dure was paced. Participants were asked to inhale for 4 s, hold
their breath for 8 s and then exhale and break for 30 s. This
sequence was repeated until the joint was smoked up to a desig-
nated line (Fig. 1). Drug administered took place in a sheltered
outdoor area. This protocol was timed and enforced by the
experimenter.
Assessments
The pleasantness rating task (PRT) tapped explicit liking and
response time to cannabis-, tobacco-, food- and neutral-related
cues. In this computer-based task, participants were presented
with a fixation cross (500 ms) followed by four types of pic-
torial stimuli in a randomised order for 3 s. Participants were
asked to rate the pleasantness of each image on a scale of −3
(very unpleasant) to +3 (very pleasant). Stimuli were matched
on brightness and complexity and included 36 critical trials.
Pictorial stimuli for cigarettes involved smoking-related
scenes and were used previously by Mogg et al. (2005).
Neutral stimuli were taken from the International Affective
Picture System (IAPS) (Lang et al. 1999). Cannabis and food
pictorial stimuli were expanded from a previous stimulus set
(Morgan et al. 2010). The task design was modified from
Metrik et al. (2015). Four versions were used and
counterbalanced across drug design. The experiment was built
and conducted using Psychopy (Peirce 2007; Peirce 2009).
The marijuana purchase task (MPT) (Aston et al. 2015;
Collins et al. 2014) and cigarette purchase task (CPT)
(MacKillop et al. 2008) assess cigarette/cannabis demand,
i.e. the relationship between cigarette/cannabis consumption
and cost (Aston et al. 2015; MacKillop et al. 2008). It is an
Table 1 Cannabis and tobacco
doses in the study drug and their
matched placebos for the four
drug conditions
Drug Condition Description
Cannabis Active 66.67 mg Bedrobinol (16.1% THC and <1% CBD).
Matched placebo 66.67 mg placebo (derived from Bedrocan; 0.07% THC)
Tobacco Active 311 mg Marlboro Red (15.48-mg nicotine, 16-mg tar, 0.8-mg nicotine yield).
Matched placebo 311 mg denicotinised tobacco (Magic 0, 0.04 mg/g nicotine)
Both active and placebo cannabis were sourced from Bedrocan® and are commercially available
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analogue of a progressive ratio operant task as consumption is
investigated under progressively increasing financial cost. It is
an established and well-validated task (Aston et al. 2015;
Chase et al. 2013; MacKillop et al. 2008; Secades-Villa
et al. 2016). In this version, participants were asked howmany
cigarettes/cannabis puffs they would hypothetically buy in the
next 3 h at increasing prices (Hitsman et al. 2008; Lawn et al.
2017). Specifically, they were asked, ‘How many cigarettes
would you smoke if they were _____ each’ or ‘How many
puffs of cannabis would you smoke if they were _____ each’.
Prices included £0 (free), 1p, 2p, 5p, 10p, 15p, 20p, 30p, 40p,
50p, 75p, £1, £1.50 £2, £2.50, £3, £3.50, £4, £5, £7.50, £10,
£15 and £20 and were presented in that order for both the CPT
and MPT. Five indices of cigarette/cannabis demand were
generated: breakpoint (cost suppressing consumption to zero),
intensity (amount of drug consumed at zero cost), Omax (peak
expenditure), Pmax (price at maximum expenditure) and elas-
ticity (the slope of the demand curve). Importantly, adjust-
ments were made for UK participants for the MPT, including
replacing ‘marijuana’ with ‘cannabis’ and ‘hits’ with ‘puffs’.
Full instructions for the CPT and the MPT are in Online
Resource 1.
Craving
This was assessed ‘right now’ at all five time points with three
single-item visual analogue scales (VAS) for cannabis, tobacco
and food. Each item began with ‘I am craving…’ with anchors
‘not at all’ and ‘extremely’.
Subjective effects
This was assessed ‘right now’ at all five time points with two
single-item VAS for euphoric and stimulated. Anchors were
‘not at all’ and ‘extremely’.
Procedure
Participants attended a baseline session followed by four exper-
imental sessions over a 4–6-week period. Eligibilitywas assessed
by telephone screening and during the baseline session. Each
experimental session began with pre-drug VAS for craving and
subjective effects. After drug administration, participants com-
pleted further VAS for craving and subjective effects at four time
points over the next hour as well as the CPT, MPTand PRT (see
Schedule of Assessments in Online Resource 1). Other tasks that
are not reported here took place in the intervening time (see
Hindocha et al. 2017a). They were reimbursed £60 for their time
on the last test day and debriefed fully.
Statistical analysis
All data were analysed using IBM Statistical Package for Social
Sciences (IBM SPSS version 23) and GraphPad Prism 7 for
Windows (GraphPad Software, La Jolla California USA,
www.graphpad.com). For the PRT, outliers >2.5 SD from the
sample mean were replaced with a score falling within 2.5 SD of
the mean following Das et al. (2015). Normality was explored
using visual inspection of diagnostic plots. When sphericity was
violated, the Greenhouse-Geisser correction was used and
corrected degrees of freedom are reported. For the PRT, we
conducted a 2 (cannabis, placebo) × 2 (tobacco, placebo) × 4
(picture type) repeated measures ANOVA on both valence and
response time measures.
Data from the purchase tasks was examined for outliers using
standard scores (Z), with a criterion of Z = 3.29 to retain maxi-
mum data (Tabachnick and Fidell 2000). Of the data, 0.02%
were outliers (Tabachnick and Fidell 2000). The outliers were
determined to be legitimate high-magnitude values and were re-
coded as one unit higher than the next lowest non-outlying value
as per Aston et al. (2015) (Tabachnick and Fidell 2000). Zero
data (i.e. when participants responded that they would not buy
purchase any cannabis or cigarettes for 0p, i.e. free) was calcu-
lated as 41% (39/96 data points) for the CPT and 7% (7/96 data
points) for the MPT, and this was due to floor effects post-drug
administration. Annual income was considered as a potential
covariate, but as it did not correlate with demand indices under
any drug (p > 0.09), it was not included (MacKillop et al. 2012).
Each demand characteristic was analysed using mixed-effects
models, which accounts for missing data whilst behaving like a
repeated measures ANOVA. Cannabis (active, placebo) and to-
bacco (active, placebo) were entered as fixed effects, and the
intercept was allowed to vary randomly. Breakpoint, intensity,
Fig. 1 Drug administration was conducted using ‘joints’, the most
common method of administering cannabis in the Europe and
Australasia (Hindocha et al. 2016). ‘Study drug’ region contained a mix-
ture of 66.67-mg cannabis (active or placebo) and 311-mg tobacco (active
or placebo) dependent on condition (see Table 1). The ‘placebo tobacco
filler’ region contained 311 mg of placebo tobacco at the bottom of the
joint (nearest to the mouth) which was not smoked. This filler was added
to improve compliance with the fixed inhalation procedure, as puff vol-
ume typically decreases towards the end of the joint, probably due to
rising heat (van der Pol et al. 2014). The stop line is the point at which
participants stopped smoking the joint, separating the two regions. It was
marked 1 cm after the ‘study drug’ to ensure complete inhalation
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Omax and Pmax were directly observed from the data. Price elas-
ticity was generated using a modification of the non-linear expo-
nential demand curve model (Koffarnus et al. 2015):
Q = Q0 × 10
k(e−αP−1), where Q = quantity consumed,
Q0 = derived intensity, k = a constant across individuals that
denotes the range of the dependent variable (cannabis puffs or
cigarettes) in logarithmic units,P = price andα = elasticity or the
rate constant determining the rate of decline in log consumption
based on increases in price (i.e. essential value). k was fixed to
log(80) = 1.9 for the MPT and log(9) = 0.9 for the CPT. Q0 was
fitted as consumption at 0 pence (free), i.e. intensity. This is a
modification of the Hursh and Silberberg (2008) exponential
demand equation and avoids poormodel fit because of exclusion
of zeros in the equation (Yu et al. 2014).
VAS scores had an additional task-specific factor of time,
which was investigated using Helmert contrasts for time (1
(pre-drug) vs 2, 3, 4, 5 (post-drug)).
Results
Demographic and drug use history
Participants were 24 (50% female) recreational cannabis and
tobacco co-users. All participants completed all assessments.
Demographics and drug use variables can be found in Table 2.
Pleasantness rating task (Fig. 2)
Valence (Fig. 2a)
There was a cannabis × picture-type interaction (F3,69 = 5.35,
p = 0.002, ηp
2 = 0.19) whereby cannabis stimuli were rated as
less pleasant under active than placebo cannabis (p = 0.01;
Fig. 2a). Food stimuli were rated as more pleasant under can-
nabis than placebo at a trend level (p = 0.053). There was a
main effect of picture type (F3,69 = 20.68, p < 0.001,
ηp
2 = 0.47). Tobacco was rated as unpleasant across all drug
conditions and neutral stimuli as around zero valence.
Response time (Fig. 2b)
We found a cannabis × picture-type interaction (F3,69 = 6.60,
p = 0.001, ηp
2 = 0.223) and a main effect of cannabis
(F1,23 = 20.33, p < 0.001, ηp
2 = 0.47). The interaction suggests
that cannabis acutely slowed response time across all stimuli
apart from cigarette stimuli.
Purchase tasks
Means (+SEM) for the demand indices derived from the MPT
and CPT for each drug condition can be found in Table 3.
Marijuana purchase task
There was a trend towards a main effect of cannabis on
breakpoint (F1,62 = 3.89, p = 0.053) where active cannabis re-
duced the first price at which consumption was zero, in compar-
ison to placebo cannabis. Therewas a trend towards amain effect
of cannabis on elasticity (F1,668 = 2.94, p = 0.09), where cannabis
increased sensitivity to cost, in comparison to placebo. There
were no other main effects or interactions with tobacco for the
other demand indices (MPT intensity, Omax or Pmax).
Cigarette purchase task (Fig. 3)
There was a main effect of cannabis on breakpoint
(F1,37.37 = 7.00, p = 0.01) where cannabis decreased the
breakpoint in comparison to placebo (Fig. 3a). There was a
main effect of cannabis for theOmax (F1,38.94 = 4.37, p = 0.04)
(Fig. 3b) where cannabis reduced the maximum expenditure.
Table 2 Demographics and drug history of participants
N = 24 (mean, SD)
% Female 50%
Age (years) 24.46 ± 3.96
SDS 0.67 ± 0.92 (range: 0–3)
FTND 0.33 ± 0.64 (range: 0–2)
Annual income (£) 14,238.33 ± 10,324.83
Cannabis + tobacco
Age of first use (years) 16.16 ± 3.94
Last used (days) 7.92 ± 9.64
Years used (years) 6.79 ± 3.94
Days per month 7.75 ± 4.43
Time to smoke 3.5 g (days) 36.58 ± 34.47
Lifetime exposures (days) 627 ± 936
Exposures in the last 90 days (days) 19.58 ± 11.27
Tobacco alone
Age of first use (years) 15.71 ± 1.94
Last used (days) 96.13 ± 313.26
Years used (years) 6.76 ± 4.58
Days per month 11.04 ± 12.68
Cigarettes per day 2.29 ± 2.74
Lifetime exposures (days) 2834 ± 7202
Exposures in the last 90 days (days) 29.75 ± 33.56
Cannabis alone
Age of first use (years) 16.32 ± 5.41
Last used (days) 466.86 ± 866.37
Years used (years) 3.31 ± 4.16
Days per month 0.82 ± 2.09
Lifetime exposures (days) 49.18 ± 97.60
Exposures in the last 90 days (days) 3.55 ± 6.39
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There was a trend for a main effect of cannabis for the Pmax
(F1,35.54 = 3.97, p = 0.054) where cannabis also reduced the
price of the maximum expenditure for cigarettes (Fig. 3c). For
all the above demand indices, there was no interaction with
tobacco. There were no main effects or interactions for the
other CPT demand indices (i.e. intensity and elasticity).
Craving (Fig. 4)
Crave food (Fig. 4a)
There was a trend towards a main effect of tobacco
(F1,23 = 4.11, p = 0.054, ηp
2 = 0.15); across all time points,
tobacco reduced craving for food in comparison to placebo.
There was also a main effect of time (F1,23 = 38.58,
p < 0.001, ηp
2 = 0.63) so participants craved food more as the
test session progressed.
Crave cannabis (Fig. 4b)
There was a main effect of time (F(1, 23) = 5.80, p = 0.025
ηp
2 = 0.20) but no other main effects or interactions.
Crave tobacco (Fig. 4c)
There were no main effects or interactions for VAS crave
tobacco.
Subjective effects
Euphoric (Fig. 5a)
Therewas a cannabis × time interaction (F1,23 = 18.13, p< 0.001,
ηp
2 = 0.44) which revealed a significant increase between canna-
bis and placebo from pre- to post-drug. Pre-drug, there was no
Table 3 Means (SEM) for the
demand indices derived from the
cigarette purchase task (CPT) and
the cannabis purchase task (MPT)
for each drug condition
Drug condition
CAN-TOB CAN TOB PLACEBO
CPT
Breakpoint 81.67 (17.79) 97.19 (19.94) 134.64 (26.24) 139.64 (19.75)
Intensity 4.50 (0.96) 4.00 (0.84) 3.86 (0.73) 3.75 (0.67)
Omax 107.08 (24.78) 122.50 (28.96) 193.57 (53.07) 149.28 (26.49)
Pmax 50 (12.08) 56.56 (13.45) 87.14 (20.18) 76.79 (13.47)
Elasticity 1.65 (0.86) 2.52 (0.78) 1.84 (0.83) 1.03 (0.83)
MPT
Breakpoint 164.75 (48.99) 145.29 (33.23) 254.63 (84.25) 214.00 (58.40)
Intensity 16.00 (3.52) 17.14 (3.40) 15.63 (2.05) 15.67 (2.29)
Omax 556.00 (143.53) 652.95 (183.86) 621.71 (123.21) 721.87 (162.47)
Pmax 65.55 (3.20) 92.19 (24.21) 81.50 (17.88) 122.50 (41.67)
Elasticity 0.27 (0.19) 0.61 (0.18) 0.11 (0.17) 0.17 (0.17)
Fig. 2 a Valence score dependent on drug condition for each picture type. b reaction time dependent on drug for each picture type (error bars show
±SEM)
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difference between active and placebo cannabis (p = 0.178);
however, active cannabis increased ‘euphoric’ ratings at all time
points post-drug (all ps ≤ 0.004). There were also main effects of
cannabis (F1,23 = 10.79, p = 0.003, ηp
2 = 0.32) and time
(F1,23 = 12.87 p = 0.002, ηp
2 = 0.36). There were no main effects
or interactions with tobacco.
Stimulated (Fig. 5b)
There was a cannabis × time interaction (F1,23 = 6.84,
p = 0.016, ηp
2 = 0.23) which revealed a significant increase
between cannabis and placebo from pre- to post-drug. Pre-
drug, there was no difference between active and placebo can-
nabis (p = 0.437); however, active cannabis increased ‘stimu-
lated’ ratings at all time points post-drug (all ps < 0.05). There
were also main effects of cannabis (F1,23 = 5.82, p = 0.024,
ηp
2 = 0.20) and time (F1,23 = 11.52, p = 0.002, ηp
2 = 0.33).
There were no main effects or interactions with tobacco.
Discussion
To the authors’ knowledge, this is the first study to examine
both the individual and combined effects of cannabis and
tobacco on drug reward processing. We found that,
compared with placebo, acute cannabis reduced liking of
cannabis- (but not cigarette-) associated stimuli and in-
creased response time to rate all picture types apart from
cigarettes. Acute cannabis administration reduced, although
not significantly, the first point where demand was zero
(breakpoint) for both cannabis puffs and cigarettes, in com-
parison to placebo. We saw reduced maximum expenditure
(Pmax) and Omax for cigarettes; however, this was not sig-
nificant for Pmax and therefore should be interpreted with
caution until it can be replicated. Overall, this suggests that
participants under the influence of cannabis became more
sensitive to price increases and therefore less likely to buy
cigarettes or cannabis at higher prices. Smoked tobacco ei-
ther alone or combined with cannabis affects demand indi-
ces for cannabis or cigarettes. Taken together, acute admin-
istration of cannabis reduced, to a degree, demand for both
cannabis and cigarettes. Finally, active cannabis increased
ratings of both euphoric and stimulated, but tobacco had
no effect on these ratings. From a public health and clinical
perspective, health-focussed campaigns should emphasise
that adding tobacco to cannabis does not modify the reward
processing of cannabis, and thus, users should be dissuaded
from mixing cannabis with tobacco. The present results
could be a product of cross-satiety between the two drugs
because this population use cannabis and tobacco together
Fig. 3 CPT indices. There were
main effects for cannabis on a
breakpoint, b Omax and c Pmax
(trend main effect) (error bars
show ±SEM)
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like many in Europe such that consuming cannabis also
reduces demand for tobacco (Hindocha et al. 2016).
Moreover, we found that there was a trend (i.e. not sig-
nificant) towards acute cannabis administration increasing
elasticity for cannabis puffs, indicating that participants were
slightly more sensitive to the price of cannabis. This is in
line with a recent study by Metrik et al. (2016) where ex-
perimentally induced craving reduced elasticity making par-
ticipants less sensitive to price and suggesting continued
purchasing despite price increases (Metrik et al. 2016). The
present results and that of Metrik et al. (2016) are in oppo-
site directions and together show that the state MPT is sen-
sitive to both satiety via acute administration and cue-
elicited craving. There were no main effects or interactions
with tobacco, suggesting that consumption of tobacco does
not alter demand for cannabis in this specific context. Future
research should investigate under conditions of cue reactiv-
ity, for both cannabis and tobacco, if cross-cue elicited crav-
ing occurs and if there would be a knock-on effect on de-
mand. It should be noted that a possible reason why there
was a minimal effect on demand for cigarettes is because
participants were non-dependent cigarette smokers and little
research has been carried out on demand, as measured by
purchase tasks, in non-dependent smokers (‘chippers’)
(Shiffman 1989). In this study, we investigated a non-
dependent population, which is an important line of investi-
gation as non-dependent, but regular users are vulnerable to
the development of addiction and the acute effects of the
drugs are not affected by residual drug use or withdrawal.
In the present study, we found that active cannabis re-
duced liking of cannabis stimuli consistent with research
suggesting that cannabis users find cannabis-related stimuli
more pleasant under placebo than active cannabis (Metrik
et al. 2015). Cannabis stimuli were always rated as pleasant
(regardless of drug condition), but after smoking active
cannabis, the ratings reduced indicative of satiety.
Moreover, we found some evidence that cannabis and to-
bacco had opposite effects on food responses; i.e. cannabis
tended to increase liking of food stimuli, consistent with
classic cannabis-induced ‘munchies’, and tobacco decreased
craving for food, as hypothesised. Interestingly, we did not
see an equivalent effect of food craving, and it is logical
that these two would increase concurrently. This may be
because the pictorial stimuli of the task were more hun-
ger-inducing than a single-item question. Indeed, food crav-
ing did increase steadily over time, but no drug effect
emerged. Under all conditions, cigarette stimuli were rated
as more unpleasant than all other stimuli, and cannabis
slowed response times to all stimuli except cigarettes.
This may be because participants had little to no depen-
dence on cigarettes; however, it may also be due to the
negative connotations and stigma associated with tobacco.
Young cannabis users often do not consider themselves
tobacco smokers even though it facilitates cannabis use
and is significantly exposing them to tobacco and its by-
products (Bélanger et al. 2011). Perhaps because of their
strong negative valence, response times to tobacco stimuli
were not modified by acute cannabis. Moreover, it should
be noted that neutral stimuli were rated with zero valence,
showing that they were indeed rated as neutral. Future re-
search will be required to investigate if there is a different
pattern of results in dependent users of cannabis and tobac-
co, who may be more sensitive to tobacco cues, and this
may vary by acute drug intoxication. Future research might
also investigate self-administration of individual and com-
bined cannabis and tobacco in humans which would give
direct demonstration of the abuse potential of the drugs
combined relative to their components; however, that was
not the aim of the present study.
Strengths and limitations
This study has several strengths including its sample size
informed by a power calculation, an ecologically valid meth-
od of drug administration and factorial investigation of can-
nabis and tobacco in a double-blind placebo-controlled de-
sign. Moreover, we attempted to control for both drugs by
asking participants to abstain for at least 12 h and we were
able to confirm this for tobacco with a CO level of <6 on
each test day. We also attempted to control for food intake
by asking participants not to eat for at least 2 h before each
testing day. However, we were not able to verify (beyond
the self-reported SDS) that participants did not have a
Fig. 5 Subjective ratings of VAS
a ‘euphoric’ and b ‘stimulated’
averaged across all participants
for all time points before (T1) and
after (T2–T5) each drug adminis-
tration. Error bars represent
±SEM
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cannabis use disorder although the mean SDS score was low
(0.67 ± 0.92). The lack of effects detected for tobacco are
unlikely to be due to an insufficient dose, as we also found
that cannabis and tobacco had significant and opposite ef-
fects of memory (Hindocha et al. 2017a). Indeed, adding
tobacco to cannabis attenuated the negative effect of canna-
bis on delayed recall in a verbal memory task. Moreover, the
lack of effect on reward-related measures is unlikely to be
due to a negative response to the drug because ratings of
euphoric and stimulated increased significantly, but there
was no difference between mixed cannabis and tobacco in
comparison to cannabis alone. Moreover, we found that can-
nabis and tobacco had independent effects on increasing
heart rate and interacting effects on increasing diastolic
blood pressure (Hindocha et al., 2017a). The doses and route
of administration of cannabis and tobacco were designed to
be comparable to real-life use, and the inclusion criteria of
smoking one ‘whole’ joint are considered a high bar as
recreational users mostly share joints. Finally, when partici-
pants experienced satiety, they stated that they would not
buy any hypothetical cannabis puffs, which led to 41% of
zero data (i.e. when participant would not purchase puffs for
zero pence; floor effects). Though we chose a method of
analysis that would allow us to control for this, this is a
substantial proportion of the data, and therefore, these results
need to be interpreted cautiously. It indicates the need for
more suitable state instruments, which do not result in floor
effects because of satiety. Finally, future studies should in-
clude comparative purchase tasks for food and validate a
purchase task for cannabis-tobacco joints.
Conclusions
In view of current changes in the medicalisation and legalisation
of cannabis, research regarding cannabis and tobacco on
addiction-related outcomes is essential. This study aimed to in-
vestigate how cannabis and tobacco, alone and combined, would
affect validated addiction-related outcomes such as drug demand,
explicit liking of associated stimuli and craving, in recreational
cannabis and tobacco joint smokers. This study further helps us
understand the mechanism bywhich recreational users may tran-
sition to harmful or dependent patterns of use. We found that,
acutely, cannabis reduced liking of cannabis stimuli and reduced
demand for both cannabis puffs and cigarettes in the purchase
task. In this population, tobacco did not influence the rewarding
effects of cannabis. Therefore, health campaigns should try to
dissuade users from adding tobacco to cannabis, as it does not
make cannabis more rewarding.
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